Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2006 Nov 17;1(7):e35.
doi: 10.1371/journal.pctr.0010035.

ADAPT: the wrong way to stop a clinical trial

Steven E Nissen  1
Affiliations
Comment

ADAPT: the wrong way to stop a clinical trial

Steven E Nissen. PLoS Clin Trials. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing Interests: SEN is the principal investigator for a large clinical trial comparing cardiovascular event rates for three nonsteroidal anti-inflammatory agents: naproxen, ibuprofen, and celecoxib. Although the study is supported by Pfizer, SEN and the Executive Committee for the trial have stipulated that no member of the trial leadership may accept any compensation from the sponsor or any other maker of drugs in this class.

Comment in

Comment on

References

    1. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) PLoS Clin Trials. 2006;1:e33. doi: 10.1371/journal.pctr.0010033. - DOI - PMC - PubMed
    1. Merck Press Office. Merck announces voluntary worldwide withdrawal of VIOXX. 2004. Available: http://www.vioxx.com/vioxx/documents/english/vioxx_press_release.pdf#sea.... Accessed 19 October 2006.
    1. Pfizer Press Office. Pfizer statement on new information regarding cardiovascular safety of Celebrex. 2004. Available: http://www.pfizer.com/pfizer/are/investors_releases/2004pr/mn_2004_1217.jsp. Accessed 19 October 2006.
    1. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–1080. - PubMed
    1. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102. [Erratum: N Engl J Med 355: 221.] - PubMed